Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136175 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00136175 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 68 participants.
The verdict
NCT00136175, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This trial will evaluate the efficacy and safety of combination chemotherapy (paclitaxel, carboplatin, and gemcitabine) prior to surgery in the treatment of patients with locally advanced transitional cell cancer of the bladder.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 1999-11 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136175
The ClinicalTrials.gov registry entry for NCT00136175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00136175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136175 about?
NCT00136175 is a clinical study titled "Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder". This trial will evaluate the efficacy and safety of combination chemotherapy (paclitaxel, carboplatin, and gemcitabine) prior to surgery in the treatment of patients with locally advanced transitional cell cancer of the bladder.
What is the current status of trial NCT00136175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 1999-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00136175?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00136175?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.